Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Broom Colin MD	2. Issuer Name and Ticker or Trading Symbol Nabriva Therapeutics plc [ NBRV ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) 1000 CONTINENTAL DRIVE, SUITE 600	3. Date of Earliest Transaction (MM/DD/YYYY) 8/19/2020
(Street) KING OF PRUSSIA, PA 19406 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	8/19/2020		M		33750	A	(1)	260000	D
Ordinary Shares	8/20/2020		S		11064	D	$0.6476	248936	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	8/19/2020		M			33750	(2)	(2)	Ordinary Shares	33750	$0	0	D

Explanation of Responses:
(1)	The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units.
(2)	On January 31, 2018, Nabriva Therapeutics plc (the "Issuer") granted the reporting person 67,500 restricted share units ("RSUs"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the "Performance Condition"), and the remaining fifty percent (50%) of the RSUs vested on the one (1)-year anniversary of the Performance Condition.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Broom Colin MD 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA, PA 19406	X

Signatures
/s/ Robert Crotty, by power of attorney		8/21/2020
**Signature of Reporting Person		Date